Psychedelic Research in
Cameroon
Cameroon appears to have a tightly controlled legal environment for narcotic drugs and psychotropic substances, with broad prohibitions on production, possession, trade, transport and import/export of substances listed in the relevant schedules. In practical terms, this means classical psychedelics are not known to have routine non-research access, and Blossom currently has no linked trials, stakeholders or events for the country.
Key Insights
A concise read of the policy, research, and stakeholder signals shaping psychedelic medicine in Cameroon.
- 1
The legal baseline is restrictive enough that non-research psychedelic access should be assumed unavailable unless a specific exemption is documented. ([sherloc.unodc.org](https://sherloc.unodc.org/cld/fr/legislation/cmr/loi_no._97-019_du_7_aout_1997_relative_au_controle_des_stupefiants_des_substances_psychotropes_et_des_precurseurs_/chapitres_ii_iii/articles_8_9/loi_97-019_.html?utm_source=openai))
- 2
The country has no Blossom-linked psychedelic trials or stakeholders, which is consistent with the absence of a visible public psychedelic research ecosystem in the sources reviewed. ([sherloc.unodc.org](https://sherloc.unodc.org/cld/fr/legislation/cmr/loi_no._97-019_du_7_aout_1997_relative_au_controle_des_stupefiants_des_substances_psychotropes_et_des_precurseurs_/chapitres_ii_iii/articles_8_9/loi_97-019_.html?utm_source=openai))
- 3
Ketamine is the only relevant compound with clear clinical-medicine context in the available sources, and the evidence supports anaesthetic use rather than any recognised psychedelic service line. ([afro.who.int](https://www.afro.who.int/sites/default/files/pdf/Health%20topics/afro_essential_medicine_price_indicator_2007.pdf?utm_source=openai))
- 4
WHO materials confirm Cameroon has a national essential medicines / health-planning infrastructure, but the sources here do not show a psychedelic-specific policy, authorisation or reimbursement programme. ([who.int](https://www.who.int/teams/health-product-policy-and-standards/assistive-and-medical-technology/essential-medicines/national-emls?utm_source=openai))
- 5
Any future change is more likely to come through research permissions or controlled medical importation than through open public access. This is an inference from the restrictive law and the lack of public approvals, not a directly stated policy. ([sherloc.unodc.org](https://sherloc.unodc.org/cld/fr/legislation/cmr/loi_no._97-019_du_7_aout_1997_relative_au_controle_des_stupefiants_des_substances_psychotropes_et_des_precurseurs_/chapitres_ii_iii/articles_8_9/loi_97-019_.html?utm_source=openai))
Research Snapshot
Blossom currently keeps Cameroon as a country index, but no psychedelic clinical trials, stakeholders or events are linked to this country in the database yet.
Missing linked records are database coverage signals, not proof that no local policy discussion, care or informal activity exists.
- Active trials
- 0
- Total trials
- 0
- Stakeholders
- 0
- Events
- 0
None marked active
No linked trials
No linked stakeholders
No linked events
Top Compounds
No headline compound signal is available from linked country trials yet.
Top Study Topics
No study-topic signal is available from linked country trials yet.
Medical Access Snapshot
Cameroon maintains strict national controls on narcotics and psychotropic substances under Law No. 97-019 (1997) and related penal code provisions; most classical psychedelics (psilocybin, MDMA, DMT, 5-MeO-DMT, mescaline, 2C-X, etc.) are effectively prohibited for non-research use and have no routine reimbursed medical pathways. Ketamine is widely used and available as an essential anesthetic in clinical and veterinary practice but novel psychedelic medicines (esketamine nasal spray, MDMA-assisted therapy, psilocybin therapy) have no known regulatory...
Regulatory Status
Cameroon's 1997 drugs law, as reflected in UNODC's SHERLOC database, prohibits cultivation, production, manufacture, trade, transport, possession, import, transit and related dealings for substances on the relevant tables, subject only to limited exceptions in the law. Public sources reviewed do not show a known regulatory approval pathway for psilocybin, MDMA, DMT, 5-MeO-DMT, mescaline or ketamine-based psychedelic therapy; ketamine appears instead in medicine-access materials as an anaesthetic medicine, so any psychiatric or psychedelic use should be treated as unconfirmed and likely restricted to exceptional clinical or research settings. ([sherloc.unodc.org](https://sherloc.unodc.org/cld/fr/legislation/cmr/loi_no._97-019_du_7_aout_1997_relative_au_controle_des_stupefiants_des_substances_psychotropes_et_des_precurseurs_/chapitres_ii_iii/articles_8_9/loi_97-019_.html?utm_source=openai))
Country Details
- Region
- Africa
- Last updated
- 4 May 2026
Country Report
Medical Only (Private)Medical Access and Reimbursement
Cameroon maintains strict national controls on narcotics and psychotropic substances under Law No. 97-019 (1997) and related penal code provisions; most classical psychedelics (psilocybin, MDMA, DMT, 5-MeO-DMT, mescaline, 2C-X, etc.) are effectively prohibited for non-research use and have no...
Open access guide →